In order to monitor the clinical outcome of pediatric patients with leukemia following allogeneic hematopoietic transplantation, tests of variable number of tandem repeat (VNTR) and sex determination by quantitative polymerase chain reaction (PCR) were performed. PCR results combined with the blast counts from 21 leukemia patients were analyzed. Complete chimerism (100% donor cells) was found in 15 cases with remission, and incomplete chimerism in six cases with relapse. In the majority of cases, complete chimerism was always associated with no detectable blasts, while blasts were often detected in association with incomplete chimerism. There is significant correlation (P Ͻ 0.0001) between the percentage of donor DNA and blast percentage in these patients. Early detection of incomplete chimerism may therefore predict a poor prognosis. In one patient (case 15), a differing percentage of donor DNA was observed between samples of bone marrow and peripheral blood collected on the same day. This may be due to the fact that allogeneic stem cells proliferate at different rates depending on their environment (bone marrow or peripheral blood). In addition, 100% donor cells found in the peripheral blood may not reflect the number of cells in the bone marrow. In case 17, asynchronous engraftment of donor cells was present between the white and red blood cell lineages, indicating that the degree of chimerism may not be the same in all cell lineages. At the time of this report, the significance of this observation is unknown and needs further investigation.
Currently, allogeneic hematopoietic stem cell transplantation plays an important role in the treatment of leukemia and other hematological and oncological disorders in children. Evaluation of the outcomes following transplantation includes the evaluation of early engraftment, graft rejection, disease status and the degree of donor chimerism. Historically early chimerism analyses were based on protein or red blood cell polymorphism or karyotyping. [1] [2] [3] [4] Since the 1980s, more sensitive tests have become available including DNA techniques such as restriction fragment length polymorphisms (RFLPs), Southern blotting and VNTR analysis. [5] [6] [7] VNTR loci are groups of DNA sequences that represent a source of highly polymorphic markers for individual identification. When compared with RFLPs and Southern blotting, VNTR has many advantages including the use of smaller quantities of DNA, ease of preparation, faster turnaround time, and elimination of restriction enzymes and radioisotopes that are required with the other two methods. The overall cost saving is also substantial. 8 Tests of sex determination are an additional tool for chimerism analysis. A target DNA sequence located in the motif of the human Y-linked testis-determination gene (SRY) was originally amplified by Cui et al 9 in a study of human sex determination at the single cell level. This highly accurate and precise test allows us to apply this technique to chimerism analysis in the case of sex-mismatch between recipient and donor.
In this study, results of PCR quantitative analysis of VNTR and sex determination in 21 pediatric patients with leukemia pre-and post transplantation were analyzed. The results were then correlated with the percentage of blasts in the peripheral blood and/or bone marrow. The feasibility and accuracy of these tests in monitoring clinical disease outcome following allogeneic bone marrow or cord blood transplantation were evaluated.
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Materials and methods
Sample collection
A total of 62 samples of peripheral blood or bone marrow were obtained from 21 pediatric patients with leukemia before and after transplantation and tested from March 1999 to March 2000. Patient age ranged from 2 to 19 years old (mean = 12). Diagnoses included acute lymphoblastic leukemia (ALL, n = 9), acute nonlymphoblastic leukemia (ANLL, n = 10), and chronic myelogenous leukemia (CML, n = 2). Samples were collected in heparin tubes and transferred to the laboratory at room temperature for both morphological evaluation and analysis of chimerism.
DNA extraction
White blood cells were isolated from whole blood by Ficoll-Paque (Amersham Pharmacia Biotech, Uppsala, Sweden). DNA was extracted from white blood cells using QIAamp DNA Blood Mini Kit (Cat. No. 51106; Qiagen, Valencia, CA, USA) according to the attached instructions. DNA concentration was measured by a spectrophotometer, GeneQuant (Pharmacia Biotech, Piscataway, NJ, USA). DNA dissolved in Milli Q water was stored at −70°C until the assay was carried out.
Polymerase chain reaction (PCR)
PCR reaction was performed in a total volume of 20 l containing 0.8 l of 25 mm MgCl 2 solution, 2.0 l of 10× PCR buffer II, 1.6 l 10 mm of each dGTP, dATP, dTTP and dCTP (PE Applied Biosystem, Foster City, CA, USA), 1 l of 25 m of each primer and 100 ng of DNA. DNA screening was first carried out by amplification of VNTR loci, APO-B, D1S80, D1S111, D17S30, and gene loci SRY and ZP3, in the pre-transplant samples of recipient and donor pair to determine the most informative locus. The latter was applied to chimerism analysis of post-transplant samples. A mixing DNA curve constructed from pre-transplant DNA of the recipient and donor pair was included in PCR for post-transplant chimerism analysis to provide quantitative information. The ratio of DNA of recipient and donor in the mixing DNA curve was 100:0, 95:5, 90:10, 75:25, 50:50, 25:75, 10:90, 5:95, 2:98, 1:99 and 0:100. Primer information regarding the VNTR loci and sex determination are listed in Table 1 . PCR conditions are shown in Table 2 .
Electrophoresis and quantification
The PCR product was run in 
Blast count
The percentage of blasts was obtained from the peripheral blood sample (n = 59) or from bone marrow (n = 3) collected the same day as the sample for VNTR analysis (Tables 3 and 4 ). The blast count was based on a 100 cell count for the peripheral samples and a 500 cell count on the bone marrow samples after Wright-Giemsa staining. These were confirmed by two observers. Flow cytometry was performed on all the samples with blasts to determine their immunophenotype. Data on flow cytometry are not reported here.
Statistics
Linear regression analysis was performed using Regression Wizard of SigmaPlot 5.0 (GraphPad Software, San Diego, CA, USA). The regression coefficients were calculated by analyzing the variance in association between independent and dependent variables. Statistical significance was determined by F-test.
Results
Pre-screening the donor-recipient pair for informative polymorphisms
DNA obtained before transplantation from donor-recipient pairs was routinely screened for four VNTR loci (APO-B, D1S80, D1S111, D17S30) and gene loci (SRY/ZP3). In this study, out of 21 cases, an informative polymorphism was seen in 28% of cases by APO-B (n = 6), 52% by D1S80 (n = 11), 14% by D1S111 (n = 3), 43% by D17S30 (n = 9) and 38% by SRY/ZP3 (n = 8). The frequency of informative polymorphism as screened by the above VNTR and gene loci can be ranked as D1S80ϾD17S30ϾSRY/ZP3 APO-BϾD1S111.
Mixing DNA curve
This curve provides a reference for the evaluation of the amounts of donor and recipient DNA in the post-transplant sample and serves as a control for each test. The sensitivity for DNA of recipient and donor was designated as 5% and 1%, respectively ( 
Analysis of chimerism in post-transplantation samples
Complete chimerism (100% donor cells) was found in 15 cases (Table 3 ) during the post-transplantation period ranging from 1 to 12 months. Six cases had persistence of mixed chimerism from 5 months to 3 years post transplant ( Table 4) . Results of hematological analysis showed that there was no evidence of blasts in either the peripheral blood or bone marrow at the time when complete chimerism was reported. However, the presence of an increased percentage of blasts correlated with a decreased percentage of donor cells in the peripheral blood of all cases except one (P Ͻ 0.0001, Figure 3 ).
Case 17, a 7 year-old girl with acute lymphoblastic leu-53 Table 1 Primer information kemia had 100% donor chimerism following an unrelated cord blood transplant. However, her blood type failed to convert to the donor's type until day 475 post transplantation. Although her own DNA was not detected, she relapsed 1 year after cord blood transplantation. She underwent a second transplant utilizing allogeneic PBSC on day 435 following her initial transplant and showed no evidence of her own DNA subsequently ( Figure 4 ).
Discussion
In this study, VNTR loci, APO-B, D1S80, D1S111, D17S30 and gene loci, SRY and ZP3 were applied to the chimerism analysis of pediatric patients with leukemia following hematopoietic stem cell transplantation. The frequency ranking for informative polymorphism in the pretransplant patient and donor pairs was as follows: D1S80ϾD17S30ϾSRY/ZP3ϾAPO-BϾD1S111. The reported frequency of informative VNTR loci varies at different laboratories. Muniz et al 14 in 1994 reported a frequency of 43% and 37% for D17S30 and D1S80 in their recipient-donor pairs; whereas Stuppia et al 15 reported frequencies of 44% for APO-B and 25% for D1S80. Sreenan et al 8 reported a frequency of 69% for D1S80, 35% for D17S30, 11.5% for APO-B and 19.2% for D1S111. The reason for such discrepancies is unclear. They may be directly due to the variety of racial and ethnic groups studBone Marrow Transplantation ied, or as a consequence of different applied alleles. Alternatively, the variations may be an indirect result of the different PCR conditions or the subsequent detection steps utilized.
Selecting the most informative VNTR locus is therefore key to the analysis of donor chimerism following allogeneic transplantation. The first choice is to obtain an individual specific band in a single VNTR locus of recipient and donor. Ideally, the size difference between these two bands should be at least 50 bp (Figure 1a) . The second choice is to find individual bands specific for the recipient and donor in two different VNTR loci. Results from these two choices should provide comprehensive information regarding either the absence or presence of DNA of both recipient and donor upon subsequent testing. The third choice is when both recipient and donor have common bands but the donor has an additional specific band in a single VNTR locus. Only partial information can be obtained but it may still be useful for determining the degree of donor chimerism. The last choice, obviously the worse scenario, is that posed by a situation when both recipient and donor have a common band but the recipient has an additional specific band. Interpretation of such a case may be problematic. Clearly, one may interpret without any hesitation that the recipient has completely engrafted when the specific band of the recipient has completely disappeared and the common band is well amplified. A problem arises, however, when the recipient's specific band is partially amplified. How one adjusts the amount of donor's DNA in relation to that of the recipient's DNA is difficult to control. Detection of the sex determination gene SRY combined with the zona pellucida gene ZP3 is an additional tool that has been successfully applied in the analysis of sex-mismatched recipient-donor pairs. There was no misdiagnosis of the sex source of blood or bone marrow samples detected in this study. SRY is specific for males, whereas ZP3, located in human chromosome 1 9 is present in both males and females. Therefore, the choice of using these genes for chimerism analysis only applies to the third and fourth choice of VNTR selection processes as mentioned above.
In this study, the sensitivity of mixing DNA curves obtained from the recipient and donor was designated as 5% and 1%, respectively. In the majority of our cases the mixing DNA curves applied reached the designated sensitivity. Only a few cases did not. This is consistent with the previous observation of Sreenan et al in 1996. 8 The reason for such failure is unclear but may be related to incomplete PCR amplification. It is also possible that the variable GC content in the amplified VNTR fragments leads to a different melting temperature. Therefore, a fixed annealing temperature in the PCR program is not necessarily optimal for all samples.
Fifteen patients with clinical remission showed complete chimerism and 0% blasts following transplant (range 1-12 months) ( Table 3) . Among six patients who relapsed (Table 4) , four had a variable period of complete chimerism with 0% blasts. Correlation between the percentage of leukemic blasts and degree of donor chimerism indicates that VNTR tests applied in this study accurately reflect the therapeutic result and the evolution of leukemia. A comparison study between VNTR results and blast level has not previously been reported in the literature. However, the correlation between mixed chimerism and relapse of leukemia was reported by Bader et al in 1997 and 1998. 16, 17 The presence of residual host cells in peripheral blood 55 Table 4 Patients with incomplete chimerism and/or bone marrow during the first 100 days after bone marrow transplantation is not an uncommon event as reported by Gaiger et al in 1991. 18 In our study, two patients had a donor DNA level below 100% without leukemic blasts detected in the peripheral blood (Table 4 ). In case 5 there was early detection of circulating blasts with a corresponding loss of complete donor chimerism (Table 4) . Immunosuppression was discontinued and the patient developed acute graft-versus-host disease. This correlated with resolution of circulating leukemia cells and return to complete donor chimerism. Although this patient was maintained in complete chimerism for a sustained period of time, he eventually relapsed. Early detection of autologous DNA in post-transplant patients may presumably be due to the detection of DNA from residual non-viable host cells. Alternatively, it may also be due to detection of DNA from leukemia cells and predict a poor outcome in these patients.
Inconsistent percentages of donor DNA were noted between bone marrow and peripheral blood samples collected on the same day in one case (case 15). Bader et al 17 in 1998 reported similar discrepancies in two patients who had complete chimerism in peripheral blood but showed 40% autologous population in their bone marrow samples. It is not surprising that allogeneic stem cells proliferate at different rates depending on their environment (bone marrow and peripheral blood). Thus we should interpret with caution a test result of complete chimerism in the peripheral blood which may or may not represent complete remission. VNTR analysis is useful for following disease status post transplant even though the peripheral blood may indicate 100% donor cells.
Case 17, originally diagnosed as ALL and transplanted with unrelated cord blood, had an asynchronous engraftment of donor cells with 100% chimerism as determined by DNA from WBC but persistence of her own blood type. Similar findings in a previous report support our observation. 19 In that study, mononuclear cells, granulocytes and lymphocytes from day 447 post transplant showed 16%, 20% and 39% donor cells, and purified T cells at day 477 demonstrated 67% donor cells in a patient with CML in clinical relapse. Clearly, the delayed red blood cell lineage engraftment was not the only concern in our case since she subsequently relapsed on day 365 post transplant. It is uncertain whether the delay in red blood cell engraftment was related to the subsequent relapse but it may certainly indicate incomplete donor engraftment and persistence of a leukemic clone. The question arises from where the leukemic clone originated. Ever since the first transplant, the patient's own DNA had never been detected. The original size of the patient's amplified DNA fragment should be located between the sizes of amplified DNA fragments of the first and second donor's band (Figure 4) . It was, therefore inconceivable that such a sensitive test as PCR reaction could miss the patient's DNA particularly since the patient had a blast count of 97.5% at this point. The problem is more perplexing since the relapse appeared to be of a similar immunophenotype. One possible explanation is that these were original blasts which existed in the transfused cord blood. One other possibility is that the presence of certain leukemia-inducing factors in the bone marrow transformed the donor stem cells into a malignant clone.
It is certain that the advancement of molecular biology techniques has changed and will continue to fundamentally change our original concepts of disease and treatment outcomes. In this study, we have summarized quantitative chimerism analysis and disease outcome in 21 pediatric patients with leukemia. Further study should be done to investigate the correlation between the degree of donor chimerism in variant cell populations and clinical outcome to better define treatment success.
